journal article·2020-05

Co‐Delivery of Paclitaxel and Interleukin‐12 Regulating Tumor Microenvironment for Cancer Immunochemotherapy

Qian Hu, Lihuan Shang, Mengmeng Wang, Kun Tu, Mei Hu, Yulin Yu, Mingwang Xu, Li Kong, Yuanyuan Guo, Zhiping Zhang

Advanced Healthcare Materials· Volume 9· Issue 10
Publisher page

Abstract

Abstract In the treatment of malignant tumors, the combination of chemotherapy that can directly kill tumor cells and immunotherapy that can activate the body's immune system and regulate tumor microenvironments is becoming one of the most promising cancer treatments. However, to co‐deliver agents with different physicochemical properties for immunochemotherapy is still facing a challenge. Here, nanoparticles are developed for the co‐delivery of the hydrophobic chemotherapeutic drug paclitaxel (PTX) and biomacromolecule interleukin‐12 (IL‐12) through the acid‐sensitive material mPEG‐Dlinkm‐PDLLA and low‐temperature expansion effect of Pluronic F127. The nanoparticles encrich in the tumor site, significantly inhibit the growth and metastasis of breast cancer cells 4T1, and prolong the overall survival of tumor‐bearing mice. The underlying immune mechanism is further explored. The combination of PTX and IL‐12 activates T lymphocytes and NK cells to release IFN‐γ, selectively inhibits regulatory T cells and induces M1‐type differentiation of tumor‐related macrophages, thereby improving tumor immunosuppressive microenvironments. This study may provide an effective strategy for cancer immunochemotherapy through co‐delivery of chemotherapeutic drug and immune cytokine by the facile thermo‐sponge nanoparticles.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Immune cells in cancer · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Liyuan Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430077 China

Tongji School of Pharmacy Huazhong University of Science and Technology Wuhan Hubei 430030 China

Tongji School of Pharmacy National Engineering Research Centre for Nanomedicine Hubei Engineering Research Centre for Novel Drug Delivery System Huazhong University of Science and Technology Wuhan Hubei 430030 China

Funding

National Natural Science Foundation of China · Huazhong University of Science and Technology

References (57)

Show source-provided references
1. 10.3322/caac.2133810.3322/caac.21338 ↗
2. 10.1038/nrclinonc.2010.22310.1038/nrclinonc.2010.223 ↗
3. 10.1016/j.immuni.2013.06.01410.1016/j.immuni.2013.06.014 ↗
4. 10.1016/j.nantod.2017.10.00810.1016/j.nantod.2017.10.008 ↗
5. 10.1038/s41467-018-03915-410.1038/s41467-018-03915-4 ↗
6. 10.1158/1078-0432.CCR-17-111710.1158/1078-0432.CCR-17-1117 ↗
7. 10.1146/annurev-immunol-031210-10132410.1146/annurev-immunol-031210-101324 ↗
8. 10.1002/anie.20180488210.1002/anie.201804882 ↗
9. 10.1007/s00262-012-1390-610.1007/s00262-012-1390-6 ↗
10. 10.1038/ncomms1344310.1038/ncomms13443 ↗
11. 10.1002/adma.20170505410.1002/adma.201705054 ↗
12. 10.1158/2326-6066.CIR-15-006410.1158/2326-6066.CIR-15-0064 ↗
13. 10.1021/acs.nanolett.7b0318610.1021/acs.nanolett.7b03186 ↗
14. 10.1001/jamaoncol.2018.515210.1001/jamaoncol.2018.5152 ↗
15. 10.1084/jem.2010026910.1084/jem.20100269 ↗
16. 10.1158/1535-7163.MCT-11-043410.1158/1535-7163.MCT-11-0434 ↗
17. 10.1016/j.canlet.2017.02.02210.1016/j.canlet.2017.02.022 ↗
18. 10.1016/j.cyto.2017.05.02410.1016/j.cyto.2017.05.024 ↗
19. 10.1002/smll.20190346210.1002/smll.201903462 ↗
20. 10.1016/j.nano.2017.04.00610.1016/j.nano.2017.04.006 ↗
21. 10.1038/cdd.2014.13410.1038/cdd.2014.134 ↗
22. 10.1016/j.biomaterials.2016.09.03410.1016/j.biomaterials.2016.09.034 ↗
23. 10.1007/s00262-014-1523-110.1007/s00262-014-1523-1 ↗
24. 10.1016/j.apsb.2019.08.00310.1016/j.apsb.2019.08.003 ↗
25. 10.1038/cdd.2013.6710.1038/cdd.2013.67 ↗
26. 10.1002/anie.20150950710.1002/anie.201509507 ↗
27. 10.1021/nl502994y10.1021/nl502994y ↗
28. 10.1016/j.jconrel.2017.11.03710.1016/j.jconrel.2017.11.037 ↗
29. 10.1021/acs.molpharmaceut.8b0056410.1021/acs.molpharmaceut.8b00564 ↗
30. 10.1016/j.jcis.2012.11.06210.1016/j.jcis.2012.11.062 ↗
31. 10.1002/term.33010.1002/term.330 ↗
32. 10.1016/j.jconrel.2012.01.04310.1016/j.jconrel.2012.01.043 ↗
33. 10.1016/j.nano.2010.02.00210.1016/j.nano.2010.02.002 ↗
34. 10.1007/s00262-011-0988-410.1007/s00262-011-0988-4 ↗
35. 10.1016/S1470-2045(14)70160-310.1016/S1470-2045(14)70160-3 ↗
36. 10.1002/ijc.3227010.1002/ijc.32270 ↗
37. 10.1002/path.413310.1002/path.4133 ↗
38. 10.1038/s41565-018-0319-410.1038/s41565-018-0319-4 ↗
39. 10.1021/acs.nanolett.7b0375610.1021/acs.nanolett.7b03756 ↗
40. 10.1016/j.celrep.2019.08.09510.1016/j.celrep.2019.08.095 ↗
41. 10.1158/0008-5472.CAN-17-348010.1158/0008-5472.CAN-17-3480 ↗
42. 10.1158/2326-6066.CIR-16-012510.1158/2326-6066.CIR-16-0125 ↗
43. 10.1038/s41467-017-00729-810.1038/s41467-017-00729-8 ↗
44. 10.1172/JCI8000710.1172/JCI80007 ↗
45. 10.1146/annurev.immunol.15.1.74910.1146/annurev.immunol.15.1.749 ↗
46. 10.1016/j.immuni.2018.09.02410.1016/j.immuni.2018.09.024 ↗
47. 10.1158/1078-0432.CCR-11-265410.1158/1078-0432.CCR-11-2654 ↗
48. 10.1016/j.biomaterials.2016.06.03210.1016/j.biomaterials.2016.06.032 ↗
49. 10.1016/j.ccell.2014.10.01810.1016/j.ccell.2014.10.018 ↗
50. 10.1158/2326-6066.CIR-17-024910.1158/2326-6066.CIR-17-0249 ↗
51. 10.4049/jimmunol.130166810.4049/jimmunol.1301668 ↗
52. 10.1016/j.intimp.2010.11.02110.1016/j.intimp.2010.11.021 ↗
53. 10.1002/smll.20170066610.1002/smll.201700666 ↗
54. 10.1016/j.jconrel.2015.04.03210.1016/j.jconrel.2015.04.032 ↗
55. 10.1038/nrd300310.1038/nrd3003 ↗
56. 10.1016/j.jconrel.2019.12.03510.1016/j.jconrel.2019.12.035 ↗
57. 10.1002/anie.20130017810.1002/anie.201300178 ↗